Treatment Of Clinical Mastitis Research Articles

Assessment of potential treatments for clinical mastitis caused by Escherichia coli in cattle using clinical and biochemical markers

Assessment of potential treatments for clinical mastitis caused by Escherichia coli in cattle using clinical and biochemical markers

Selective treatment of clinical mastitis: Assessment of the Net Cash Impact on Dairy Farms Under Diverse Scenarios. A European Perspective.

Selective treatment of clinical mastitis (STCM) potentially reduces antimicrobial use without negative implications on cow's milk production or health. However, this approach comes with additional costs. The aim of this study was to evaluate the net cash impact (NCI) of implementing STCM compared with blanket treatment of clinical mastitis (BTCM) under different diagnostic-test turnaround times (24 h, 14 h, and 8 h) using a stochastic partial budget analysis with Monte Carlo simulation. The target population was European commercial dairy herds; therefore, the model inputs were primarily from European sources. Additionally, variables associated with dairy management programs were obtained from USDA sources, worldwide multisite clinical trials, and expert opinion. The output was calculated by subtracting the cost of STCM from the cost of BTCM and it represented the expected NCI if a herd switched from BTCM to STCM. Depending on the time-to-treatment efficiency and diagnostic-test turnaround time, the expected mean NCI, assuming that STCM has no impact on the cow's future health or production, ranged from +€8.7 to +€12.4 per case with 72.4% to 84.8% of the iterations being ≥ €0. Moreover, using the numerically favorable health and production effects of STCM reported in the literature, the expected mean NCI ranged from +€44.5 to +€48.1 per case with 93.6% to 95.4% of the iterations being ≥ €0. The variables with the greatest contribution to NCI variance were proportion of gram-positive cases (39.2% of the variance) and days out of the tank for treated cows (22.0%). However, if future cow's health and production were accounted for, culling risk (24.6%), recurrence risk (19.4%), and milk yield (10.6%) would have the greatest contribution to NCI. The sensitivity analysis indicated that farms with high clinical mastitis incidence, low proportion of gram-positive cases, large number of days out of the tank for treated cows, higher milking frequency or using automatic milking systems, not using the highest priced diagnostic tests, and having high antimicrobial treatment costs are the best candidates for STCM. Improving time-to-treatment efficiency, for example, by using a rapid diagnostic test, leads to a favorable NCI, while high daily milk yield and milk price enhances the NCI in already positive scenarios. Finally, the cash flow entirely depends on future cow's health and milk yield. In conclusion, results indicate that overall, STCM is a practice that positively impacts the NCI of many herds.

Evaluation of point-of-care tests for identification of pathogens to inform clinical mastitis treatment decisions in pasture- and confinement-managed dairy cows in Australia

To support antimicrobial stewardship in livestock production, there is a growing array of point of care diagnostics to guide antimicrobial treatment. The primary objective of this observational study was to evaluate the diagnostic performance of 5 point of care tests currently available in Australia for guiding lactational treatment of non-severe clinical mastitis. A secondary objective was to describe the pathogen profiles of mastitis-causing organisms in cows managed in barns ("intensive") and on pasture ("non-intensive"). Foremilk samples (n = 641) were collected by farm staff in dairy herds in Australia (n = 30) and tested at a university laboratory using a reference test and 5 index tests. The reference test was aerobic culture on Trypticase Soy Agar with 5% sheep blood followed by MALDI-TOF for identification of isolates. The following point of care tests were evaluated as index tests: Accumast®, biplate, Check-Up, Mastatest®, and 3M Petrifilm. We found that 23% of samples were contaminated, with the median herd contamination prevalence being 22%. After excluding contaminated samples, the most common diagnoses (according to the reference test) in intensive herds were no growth (31.7%), Klebsiella spp. (28.1%), E. coli (15.0%), and Strep. uberis (8.4%). The most common diagnoses in non-contaminated samples from cows in non-intensive herds were Strep. uberis (35.0%), no growth (26.9%), and E. coli (13.3%). After 24 h of incubation, all index tests demonstrated limited diagnostic sensitivity for identification of pathogens of interest (range: 0.06 to 0.63). Diagnostic performance was better at the group-level, with sensitivity and specificity for identification of non-contaminated gram-positive growths (i.e., cases that are widely considered to be candidates for antimicrobial treatment) being 0.84 and 0.75 (biplate), 0.76 and 0.90 (Accumast), 0.89 and 0.79 (Check-Up), 0.67 and 0.83 (Petrifilm), and 0.55 and 0.81 (Mastatest). In intensive herds, 22.7 to 40% of cases were classified as antimicrobial treatment candidates by index tests, which was less than for cows in non-intensive herds (41.3 to 61.0%). Despite limited diagnostic reliability at genus and species level, and the need to ensure samples are collected aseptically, our findings indicate that implementation of selective treatment protocols using the tests evaluated in this study would likely reduce antimicrobial usage in Australian herds.

Effects of extending dairy cow longevity by adjusted reproduction management decisions on partial net return and greenhouse gas emissions: A dynamic stochastic herd simulation study

Prolonging dairy cattle longevity is regarded as one of the options to contribute to more sustainable milk production. Because failure to conceive is one of the main reasons for culling, this study investigates how adjustments in reproduction management affect partial net return at herd level and greenhouse gas emissions per unit of milk, using a dynamic stochastic simulation model. The effects of reproduction decisions that extend cattle longevity on milk yield, calving interval and pregnancy rate were derived from actual performance of Dutch commercial dairy cows over multiple lactations. The model simulated lactations, calving, and health status events of individual cows for herds of 100 cows. Scenarios evaluated differed in the maximum number of consecutive AI attempts (4, 5, or 6 services), or the production threshold (20, 15, or 10 kg of milk/d) at which cows that failed to conceive are culled (reproductive culling). Annual partial net return was computed from revenues of sold milk, calves, and slaughtered cows, and the costs from feed consumption, rearing replacement heifers, AI services, and treatment for clinical mastitis and lameness. Greenhouse gas emissions were computed for feed production, enteric fermentation, and manure management, and were expressed as total CO2 equivalents (CO2-eq). Average age at culling increased with an increased maximum number of AI services. This increase was larger when going from a maximum of 4 to 5 AI attempts (108 d) than from a maximum of 5 to 6 attempts (47 d). Similarly, the average age at culling increased from 1,968 to 2,040 and 2,132 d when the threshold for reproductive culling decreased from 20, to 15 and 10 kg of milk/d, respectively. Average annual partial net return increased by 1.1% from €165,850 per 100 cows at a maximum of 4 AI to €167,670 per 100 cows at a maximum of 6 AI, and increased by 4.3% from €161,210 per 100 cows at a reproductive culling threshold of 10 kg/d to €168,190 per 100 cows at a threshold of 20 kg/d. Greenhouse gas emissions decreased by 1.2% from 0.926 to 0.915 kg CO2-eq per kg of fat- and protein-corrected milk (FPCM) with an increase in a maximum number of AI from 4 to 6 AI. Conversely, greenhouse gas emissions increased by 0.2% from 0.926 kg at a threshold of reproductive culling of 20 kg/d to 0.928 kg CO2-eq/kg FPCM at a threshold of 10 kg/d. Although lowering the threshold for reproductive culling has the potential to extend cattle longevity more than increasing the maximum number of AI services, only the increase in AI services benefits a farm's partial net return, while reducing greenhouse gas emissions.

Selective treatment of clinical mastitis in dairy cows

Selective treatment of clinical mastitis in dairy cows

Effect of Photobiomodulation With Laser on The Composition, Production and Quality of The Milk of Cows with Clinical Mastitis

Objective: This study assesses the impact of LASER photobiomodulation (808nm at 1400 mW and 637nm at 100 mW, with a 2-minutes irradiation per wavelength, total dose: 1.4 W/cm² and 1 W/cm², respectively) on milk composition and quality in cows suffering from clinical mastitis. Theoretical Framework: Research indicates LASER photobiomodulation's potential in improving animal health, yet there’s a gap in specific therapeutic protocols for treating clinical mastitis in cows using this technology. Methodology: The study involved 20 cows with clinical mastitis. Their mammary quarters were assessed for fat and protein composition, Somatic Cell Count, Urea Nitrogen levels, Microbiological Culture, and Antibiotic Sensitivity and Milk production. Comparisons were made between two groups over six days: one receiving a combination of antibiotics and LASER photobiomodulation therapy, and a control group receiving only antibiotics. Results and Conclusion: LASER photobiomodulation significantly aided the treatment of clinical mastitis in conjunction with antibiotics. This combination not only helped in curing mastitis but also reduced the Somatic Cell Count and increased milk production, marking it as a viable alternative therapy. Implications of the Research: This study contributes to establishing a more effective treatment protocol for clinical mastitis, combining photobiomodulation with traditional antibiotic methods. Originality/Value: This pioneering research showcases the use of a photobiostimulation device as a supplementary treatment for controlling clinical mastitis in dairy cows, integrated with antibiotic therapy. It underscores the enhanced efficiency of such combined treatments, contributing to the Sustainability.

Dairy farmers' considerations for antimicrobial treatment of clinical mastitis in British Columbia and Alberta, Canada.

Clinical mastitis (CM) treatment decision-making is a multifaceted process that remains relatively understudied, despite CM being one of the most prevalent diseases on dairy farms worldwide, contributing greatly to the use of antimicrobials in the dairy industry. This study aimed to gain insights into decision-making mechanisms employed by dairy farmers in British Columbia and Alberta, Canada, when dealing with CM. Interviews were held with 15 dairy farmers in the Canadian provinces of British Columbia and Alberta and analyzed using reflexive thematic analysis to develop both the decision-pathway and overarching themes influencing the CM decisions by farmers in this region. The analysis generated a decision-making process that begins with identification and classification of CM, guided by visual characteristics of milk and the udder, available milk production and quality data, presence of systemic signs, and additional diagnostics. Subsequently, CM cases are assessed based on the likelihood of cure, value of the cow, and herd goals to decide whether antimicrobial treatment is desired. Next, a treatment choice is made by evaluating severity and urgency of the case, availability of drugs and timing of the case. Finally, definition of treatment success and progression over time following the treatment decision guides the termination of treatment. Three overarching themes were generated that shape the decision-making process: 'Personal attributes', including personal approach and experiential knowledge; 'Inter-actor dynamics', such as shared decision-making and dynamics among producers, veterinarians, and milkers; and 'Moving beyond protocols', which highlights the dynamic nature of mastitis decision-making. These insights have the potential to inform the development of effective interventions to improve CM antimicrobial use that align with the reality of farming operations within Western Canada, and potentially beyond.

Adoption and decision factors regarding selective treatment of clinical mastitis on Canadian dairy farms

As clinical mastitis (CM) treatments are responsible for a large portion of antimicrobial use on dairy farms, many selective CM treatment protocols have been developed and evaluated against a blanket treatment approach of CM cases. Selective treatment protocols use outcomes of diagnostic tests to exclude CM cases from antimicrobial treatment when they are unlikely to benefit. To tailor interventions to increase uptake of selective treatment strategies, a comprehension of current on-farm treatment practices and factors affecting treatment decisions is vital. Two questionnaires were conducted among 142 farms across 5 provinces participating in the Canadian Dairy Network for Antimicrobial Stewardship and Resistance in this cross-sectional study. Self-reported adoption of selective CM treatments by dairy farmers was 64%, with median of 82% of cows treated in those herds using selective treatment. Using logistic regression models, the odds to implement a selective CM treatment protocol increased with a decreasing average cow somatic cell count. No other associations were identified between use of a selective CM treatment protocol and farm characteristics (herd size, CM incidence, province, milking system, and housing system). Three subsets of farmers making cow-level CM treatment decisions were identified using a cluster analysis approach: those who based decisions almost exclusively on severity of clinical signs, those who used various udder health indicators, and farmers who also incorporated more general cow information such as production, age, and genetics. When somatic cell count was considered, the median threshold used for treating was >300,000 cells/mL at the last Dairy Herd Improvement test. Various thresholds were present among those considering CM case history. Veterinary laboratories were most frequently used for bacteriological testing. Test results were used to start, change, and stop treatments. Regardless of protocol, reasons for antimicrobial treatment withheld included cow being on a cull list, having a chronic intramammary infection, or being at end of lactation (i.e., close to dry off). If clinical signs persisted after treatment, farmers indicated that they would ask veterinarians for advice, stop treatment, or continue with the same or different antibiotics. Results of this study can be used to design interventions targeting judicious mastitis-related antimicrobial use, and aid discussions between veterinarians and dairy producers regarding CM-related antimicrobial use.

Clinical mastitis treatment decisions

Mastitis is the most common bacterial disease of lactating cows1,2 and throughout the world accounts for the majority of antibiotic doses given on dairy farms.3-8 Many of these antibi­otic doses are unnecessary because of high spontaneous cure rates for many intramammary infections (IMI) affecting other­wise healthy cows. Mastitis is recognized based on the extent of the inflammatory response after IMI is established. It is consid­ered “subclinical” when the immune response causes increased somatic cell count (SCC), but the cow remains healthy with no visible changes in the milk or udder. Milk from cows with sub­clinical mastitis can be comingled with milk from healthy cows and sold, thus treatment during lactation is not usually cost ef­fective and most of these cases are treated with antibiotics at dry off. Clinical mastitis occurs when the immune response to IMI results in visually abnormal milk with or without second­ary signs. Fortunately, few cases of clinical mastitis cause sys­temic signs that require immediate therapy, but abnormal milk may not be sold for human consumption, so farmers emphasize interventions (such as antibiotic therapy) that are perceived to hasten the return to normal milk. Non-severe cases of mastitis that present with abnormal milk, or abnormal milk accompa­nied by localized swelling of the udder account for about 85% of all CM cases.9-11 Mastitis caused by many opportunistic bacteri­al pathogens often have high rates of spontaneous bacteriologi­cal clearance, so on many farms, most cases of clinical mastitis occurring in otherwise healthy cows do not benefit from antibi­otic therapy. Treatment protocols for non-severe clinical masti­tis should include an assessment of the immune capabilities of the cow, the likely etiology of the case, a review of the medical history of the cow and an assessment of the probability that she will remain productive long enough to recoup the costs (includ­ing discarded milk) associated with treatment. The purpose of this paper is to review treatment decisions for non-severe clini­cal mastitis, emphasizing evidence-based criteria that indicate when antibiotic therapy is beneficial to the cow.

The Economic Evaluation of Mastitis Control Strategies in Holstein-Friesian Dairy Herds.

The economic evaluation of mastitis control is challenging. The objective of this study was to perform the economic evaluation of mastitis control, under different intervention scenarios, quantifying the total cost of mastitis caused by S. aureus in Holstein cows in Argentina. A model was set for a dairy herd of Holstein cows endemically infected with S. aureus. A basic mastitis control plan including proper milking procedures, milking machine test, dry cow therapy, and treatment for clinical mastitis, was compared against other more complex and costly interventions, such as segregation and culling of chronically infected cows. Sensitivity analysis was performed by modifying the intramammary infection transition probabilities, economic parameters, and efficacy of treatment strategies. The basic mastitis control plan showed a median total cost of USD88.6/cow per year, which was close to the infected cows culling scenarios outputs. However, the segregation scenario was the most efficient, in which the total cost was reduced by about 50%. Such cost was more sensitive to probabilities and efficacy than the economic parameters. The model is flexible and can be customized by producers and veterinarians according to different control and herd settings.

Comparative efficacy of local and parenternal therapies in treatment of clinical mastitis in buffaloes

Comparative efficacy of local and parenternal therapies in treatment of clinical mastitis in buffaloes

Selective treatment of nonsevere clinical mastitis does not adversely affect cure, somatic cell count, milk yield, recurrence, or culling: A systematic review and meta-analysis

Treatment of clinical mastitis (CM) contributes to antimicrobial use on dairy farms. Selective treatment of CM based on bacterial diagnosis can reduce antimicrobial use, as not all cases of CM will benefit from antimicrobial treatment, e.g., mild and moderate gram-negative infections. However, impacts of selective CM treatment on udder health and culling are not fully understood. A systematic search identified 13 studies that compared selective versus blanket CM treatment protocols. Reported outcomes were synthesized with random-effects models and presented as risk ratios or mean differences. Selective CM treatment protocol was not inferior to blanket CM treatment protocol for the outcome bacteriological cure. Noninferiority margins could not be established for the outcomes clinical cure, new intramammary infection, somatic cell count, milk yield, recurrence, or culling. However, no differences were detected between selective and blanket CM treatment protocols using traditional analyses, apart from a not clinically relevant increase in interval from treatment to clinical cure (0.4 d) in the selective group and higher proportion of clinical cure at 14 d in the selective group. The latter occurred in studies co-administering nonsteroidal anti-inflammatories only in the selective group. Bias could not be ruled out in most studies due to suboptimal randomization, although this would likely only affect subjective outcomes such as clinical cure. Hence, findings were supported by a high or moderate certainty of evidence for all outcome measures except clinical cure. In conclusion, this review supported the assertion that a selective CM treatment protocol can be adopted without adversely influencing bacteriological and clinical cure, somatic cell count, milk yield, and incidence of recurrence or culling.

Pegbovigrastim treatment resulted in an economic benefit in a large randomized clinical trial in grazing dairy cows

This randomized controlled trial on 4 commercial grazing dairy farms investigated whether pegbovigrastim (PEG) treatment affected partial net return as calculated from milk revenues and costs for feed, medical treatments [clinical mastitis, uterine disease, and other diseases (i.e., any medical treatment that was not intended for clinical mastitis or uterine disease)], inseminations, and culling during a full lactation in grazing dairy cows. We also explored the effect of potential interactions of PEG treatment with parity, prepartum body condition score, and prepartum nonesterified fatty acids concentration on partial net return, milk revenues, and the costs mentioned above. Holstein cows were randomly assigned to 1 of the 2 following trial arms: a first PEG dose 9.4 ± 0.3 (mean ± standard error) days before the calving date and a second dose within 24 hours after calving (PEG: primiparous = 342; multiparous = 697) compared with untreated controls (control: primiparous = 391; multiparous = 723). The effect of PEG treatment on the outcomes of interest expressed per year was tested using general linear mixed models. Results are presented as least squares means ± standard error. Overall, PEG treatment increased the partial net return, resulting in an economic benefit per cow per year of $210 ± 100. The cost of treatment of clinical mastitis was lower for PEG treated cows compared with control cows ($9 ± 3). The largest nonsignificant difference was seen for the cost of culling; additionally, PEG treatment numerically reduced the cost of culling by $145 ± 77.

Comparison of the Efficacy of Intramammary or Injectable Antibiotic Administration against Staphylococcal Mastitis in Ewes.

The objectives of the work were (a) to compare the efficacy of two routes for antibiotic administration in the treatment of mastitis in ewes and (b) to assess the potential importance of the timing of the initiation of the therapeutic regime on the outcome of the treatment. The ewes were allocated at random into three equal groups; intramammary inoculation with a Staphylococcus simulans isolate was performed, and clinical mastitis developed. The ewes in groups T1 (n = 6) and T2 (n = 6) were treated by the intramammary administration of ampicillin and dicloxacillin (two administrations with a 12-h interval). The ewes in group T3 (n = 6) were treated by the intramuscular injection of ampicillin and dicloxacillin (0.75 mL per 10 kg bodyweight, three injections with a 24-h interval). In the ewes in groups T1 and T3, treatment started immediately when the clinical signs of mastitis were first detected during the periodic examination of the ewes; in the ewes in group T2, treatment started 24 h after the clinical signs of mastitis were first detected. The animals were monitored clinically; mammary secretion samples were collected for bacteriological and cytological examinations. The median duration of the clinical signs was 4.75, 7.13, and 4.75 d for T1, T2, and T3; significant differences in clinical severity between the groups were seen until the 7th day post-treatment. The median duration of bacterial recovery was 3.25, 8.00, and 8.00 d for T1, T2, and T3; significant differences in the frequency of bacterial recovery between the groups were seen until (64.1%, 94.9%, and 96.2% of the samples) and after (2.9%, 16.7%, and 11.8%) the 7th day post-treatment. The median period required for the complete cure (clinical, bacteriological, and cytological) was shorter in the T1 than in the T2 and T3 ewe groups: 20.0, 32.0, and 24.5 d, respectively. The findings cover a gap in the available literature regarding the treatment of clinical mastitis in ewes. Early treatment resulted in the improved cure of the infection. The comparison of the intramammary and injectable routes for antibiotic administration indicated some benefit for the former, primarily in the post-treatment somatic cell counts.

Genetic associations between mastitis, milk electrical conductivity, and milk flow rate in temperate dairy cows in tropics

Milk electrical conductivity and milk flow rate are potential indicators in selection targeting mastitis resistance. This study aimed to estimate the genetic parameters for clinical mastitis, average daily milk electrical conductivity (EC), milk flow rate (FR), and milk yield (MY) for the first lactation of imported Jersey and Jersey-Friesian dairy cows in Sri Lanka. Genetic parameters for mastitis traits, the prevalence of clinical mastitis in each cow, the duration of clinical mastitis treatment, and the number of episodes of mastitis were estimated using univariate sire models with permanent environmental effect of the cow added to models for prevalence of clinical mastitis in each day of milk over the whole lactation, or within the first 100-days of milk. The genetic parameters for the traits EC, FR, and MY over the whole lactation and for these traits defined for 30-day intervals were estimated using univariate animal models. For all mastitis traits, a zero heritability was estimated under both normal and logit scales. Heritabilities of EC and FR ranged from 0.02 to 0.11 and from 0.02 to 0.14, respectively. Genetic correlations between MY and EC and between MY and FR around peak milk yield were 0.25 ± 0.46 and 0.46 ± 0.29, respectively. Based on the heritability estimates for mastitis, dairy cows in this study cannot be directly selected for mastitis resistance, but indirect selection via EC and FR is feasible. Recording all cases of both sub-clinical and clinical mastitis in subsequent lactations is recommended to aid selection of dairy cows for mastitis resistance.

Different European Perspectives on the Treatment of Clinical Mastitis in Lactation.

As part of the European Network for Optimization of Veterinary Antimicrobial Treatment (ENOVAT), a webinar on the topic “Mastitis Treatment in Lactation” was held, in which eight mastitis experts from different European countries (Spain, The Netherlands, Estonia, Ireland, Poland, Finland, Germany, and Italy) presented their treatment approaches for clinical mastitis in lactation. The aim of this study was to compare the therapeutic approaches to identify commonalities and differences. In all eight participating countries, the decision to start treatment is usually made by the veterinarians, while the farm personnel are responsible for treatment administration. Antibiotic treatment is then typically administered intramammarily. The treatment duration often depends on the label instructions and is frequently extended if Staphylococcus aureus or Streptococcus uberis is involved. Administering supportive therapy, especially non-steroidal anti-inflammatory drugs (NSAIDs) is an established practice in all countries. Penicillin is the first-choice drug for the treatment of mastitis in an increasing number of countries. The use of critically important antimicrobials (CIAs) such as quinolones and third- and fourth-generation cephalosporins is at a low level in Finland and The Netherlands. In Estonia, Germany, Italy, and Spain, the use of CIAs is declining and is only allowed if milk samples are analyzed in advance following the legal framework. Systems for monitoring antibiotic use are being introduced in more and more countries. This exchange of different views will help the European countries to move towards a common high standard of antimicrobial stewardship in veterinary medicine.

Use of Antibiotics against Bacterial Infections on Dairy Sheep and Goat Farms: Patterns of Usage and Associations with Health Management and Human Resources.

The objectives of the study were (a) to describe the patterns of antibiotic usage against four major clinical problems and (b) to evaluate factors that were associated with their use on small ruminant farms. Sheep and goat farmers mostly administered the antibiotics to animals at the dose prescribed (80.4%) and observed the necessary withdrawal period (98.7%), but fewer farmers (22.3%) weighed the animals to calculate their bodyweight before antibiotic administration. For the treatment of clinical mastitis, oxytetracycline, penicillin and streptomycin were the antibiotics used more frequently; 2.03 different antibiotics were used per sheep flock and 2.06 per goat herd, most frequently administered in injectable forms (88.8% of farms). In cases of abortion, oxytetracycline was administered more frequently; 1.12 different antibiotics were used per sheep flock and 1.03 per goat herd. In 94 farms (21.2%), routine administration of antibiotics was performed to newborns; oxytetracycline and ampicillin were administered more often. For the treatment of pneumonia in newborns, oxytetracycline, penicillin and tulathromycin were used more frequently; 1.33 antibiotics were used per sheep flock and 1.29 per goat herd. For the treatment of diarrhoea in lambs and kids, oxytetracycline, amoxicillin and penicillin were the antibiotics used more frequently; 1.34 antibiotics were used per sheep flock and 1.59 per goat herd. Results of multivariable analyses indicated 16 variables associated with the various outcomes for usage of antibiotics for the treatment of the above clinical problems. Of these, 11 variables were associated with the farmers: education of farmers was significant for three outcomes; the age, the experience, the professional involvement and farming family tradition of farmers and the daily period spent at the farm were each significant for one outcome.

The use of ozone in the treatment of bovine mastitis: Report case

Mastitis is defined as inflammation of the mammary gland and is characterized by causing significant alterations in the composition of milk and economic losses and endless perjuries to the dairy industry. For this reason, and in view of the growing demand for antibiotic-free and quality products for human consumption, alternatives are being sought for current broad-spectrum antibiotic-based mastitis treatments. Within this framework, this article aims to demonstrate through a case report the effectiveness of the use of ozonized solutions in the treatment of clinical mastitis in dairy cows. For which a cow that presented clinical mastitis in 2 quarts was treated, with an ozonated solution (10 ml of solution in total, 5 ml of ozonated sunflower oil plus 5 ml of ozonated physiological serum in a concentration of 12 mg/ml), this treatment was compared with a usual commercial antibiotic treatment (Masticine L). At the end of the treatments, a favorable change was perceived in terms of visible physical aspects in both treatments, the antibiotic having a better performance in this regard, however the treatment with ozonized solution had favorable effects in terms of milk composition, improving its quality and lowering treatment costs therefore the use of intramammary ozonated solutions is recommended for the treatment of clinical mastitis in dairy cows.

Cell Differentiation of Bovine Milk Control Samples to Improve Prognosis of Mastitis Cure.

To optimise udder health at the herd level, identifying incurable mastitis cases as well as providing an adequate therapy and culling strategy are necessary. Cows with clinical mastitis should be administered antibiotic medication if it is most likely to improve mammary cure. The somatic cell count (SCC) in milk of the monthly implemented Dairy Herd Improvement (DHI) test represents the most important tool to decide whether a cow has a promising mammary cure rate. Differential cell count (DCC) facilitates the specification of the immunological ability of defence, for example by characterising leukocyte subpopulations or cell viability. The aim of this study was to assess the DCC and cell viability in DHI milk samples regarding the cytological (CC) and bacteriological cure (BC) of the udder within a longitudinal study, thereby gaining a predictive evaluation of whether a clinical mastitis benefits from an antibiotic treatment or not. The cows enrolled in this study had an SCC above 200,000 cells/mL in the previous DHI test. Study 1 assessed the CC by reference to the SCC of two consecutive DHI tests and included 1010 milk samples: 28.4% of the mammary glands were classified as cytologically cured and 71.6% as uncured. The final mixed logistic regression model identified the total number of non-vital cells as a significant factor associated with CC. An increasing amount of non-vital cells was related to a lower individual ability for CC. Cows which were in the first or second lactation possessed a higher probability of CC than cows having a lactation number above two. If animals developed a clinical mastitis after flow cytometric investigation, the BC was examined in study 2 by analysing quarter foremilk samples microbiologically. Taking 48 milk samples, 81.3% of the mammary glands were classified as bacteriologically cured and 18.7% as uncured. The percentage of total non-vital cells tended to be lower for cows which were cured, but no significance could be observed. This study revealed that the investigation of the proportion of non-vital cells in DHI milk samples can enhance the prognosis of whether an antibiotic treatment of clinical mastitis might be promising or not. Prospectively, this tool may be integrated in the DHI tests to facilitate the decision between therapy or culling.

Meloxicam in Combating Clinical Mastitis: Nanotechnology-Driven Hope and Opportunities.

Mastitis has well-recognized harmful effects on dairy farm profitability. Furthermore, mastitis impairs the milk component synthesizing ability of secretary tissues. Various therapies are available for the treatment of clinical mastitis. Meloxicam exhibits preferential binding to Cyclooxygenase-2 (COX-2) receptor and consequently generates fewer negative gastrointestinal side effects than nonspecific COX inhibitors such as flunixin meglumine and ketoprofen. Toward this end, research efforts directed at understanding the use of meloxicam alone and in combination with other antibiotics to improve milk quality and production. Therefore, in this review, we have highlighted the mechanism, biopharmaceutical challenges, and merits of meloxicam usage in dairy cattle mastitis. In addition, we also presented the integration of artificial neural network, in silico docking, and nanotechnology-driven topical drug delivery cargo as future opportunity for efficient delivery of meloxicam in the management of clinical mastitis.